This study is the first to elucidate the impact of albuminuria and renal dysfunction on the anemia-improving effects of SGLT2 inhibitors by analyzing real-world clinical data from patients exhibiting a spectrum of albuminuria severity and eGFR levels. This evidence concerns the gene SLC5A2 and anemia (phenotype).